- LexaGene (LXG) has completed a statement of work with a biopharma company
- The study showed the MiQLab System to be sensitive, reliable, reproducible, and tolerant to materials commonly used or produced in the manufacturing process
- The automated nature of the MiQLab System makes in-line screening for manufacturing contaminants possible
- LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers
- Lexagene Holdings Inc. (LXG) opened trading at C$0.255
LexaGene (LXG) has completed a previously-announced statement of work with a biopharma company.
The biopharma company recently purchased a MiQLab System.
Dr. Jack Regan, LexaGene’s CEO and Founder, commented on the news.
“We are very pleased with how quickly this study was completed and the quality of the data generated. This validation study showed the MiQLab System to be sensitive, reliable, reproducible, and tolerant to materials (i.e., inhibitors) commonly used or produced in the manufacturing process. It also provides quantitative information on targeted contaminants. Furthermore, the data proved the MiQLab System is comparable to gold-standard techniques performed by skilled scientists. These benefits and the automated nature of the MiQLab System make in-line screening for manufacturing contaminants possible. Such in-line screening would allow for more rapid detection of contaminants, which mitigates the risk of significant losses and improves the productivity of the plant and the safety of their products.”
Dr. Regan continued,
“Now that the study is complete, I look forward to discussing with our biopharma customer the next steps that are needed to get our technology broadly adopted for their manufacturing testing needs.”
The validation study was conducted using MiQLab Systems equipped with MiQLab Microbial QC Panels (C2) that screen processed samples for Cutibacterium acnes, Escherichia coli (E. coli), Staphylococcus, Streptococcus and Mycoplasma.
The study was conducted primarily at LexaGene using proprietary materials from the biopharma company.
LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers. The System is designed for on-site usage and uses real-time PCR chemistry.
Lexagene Holdings Inc. (LXG) opened trading at C$0.255.